Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Article in Frontiers in Oncology (April 2024)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
Article in New England Journal of Medicine (February 2024)
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Article in Frontiers in Oncology (June 2023)